Posts tagged ‘Food and Drug Administration’

23/11/2015

China’s Sun Paper to build $1.36 billion facility in U.S. | Reuters

China’s Shan Dong Sun Paper Industry Joint Stock Co (002078.SZ) said on Monday it would spend about $1.36 billion to build a pulp mill in the United States in its first investment outside the country.

The facility is expected to break ground in 2016 and start operations in 2018, Sun Paper spokesman Song Weihua told Reuters.

The mill in the southeastern state of Arkansas is slated to make fluff pulp, a raw material for diapers and sanitary products.

On Friday Sun Paper Chairman Li Hongxin signed a memorandum of understanding for this at a ceremony in Jinan which was attended by U.S. Commerce Secretary Penny Pritzker and Arkansas Governor Asa Hutchinson.

The U.S. Food and Drug Administration has approved the company to manufacture paper at the mill, Sun Paper said in a statement to the Shanghai Stock Exchange on Monday.

The investment by the northern China-based company is the latest in a slew of deals by Chinese manufacturers looking to diversify their operations and take advantage of initiatives and rebates in western countries.

Shandong Tranlin Paper Co Ltd invested $2 billion in a paper and fertilizer plant in Virginia last year. (reut.rs/1PUY1r4)

Sun Paper declined to give details on its financing of the project, although sources said the company is likely to involve a combination of equity and debt.

Source: China’s Sun Paper to build $1.36 billion facility in U.S. | Reuters

03/04/2015

A New Cancer Drug, Made in China – China Real Time Report – WSJ

Xian-Ping Lu left his job as director of research at drug maker Galderma R&D in Princeton, N.J., to co-found a biotech company to develop new medicines in his native China. As the WSJ’s Shirley S. Wang reports:

It took more than 14 years but the bet could be paying off. In February, Shenzhen Chipscreen Biosciences’ first therapy, a medication for a rare type of lymph-node cancer, hit the market in China.

The willingness of veterans like Dr. Lu and others to leave multinational drug companies for Chinese startups reflects a growing optimism in the industry here. The goal, encouraged by the government, is to move the Chinese drug industry beyond generic medicines and drugs based on ones developed in the West.

Chipscreen’s drug, called chidamide, or Epidaza, was developed from start to finish in China. The medicine is the first of its kind approved for sale in China, and just the fourth in a new class globally. Dr. Lu estimates the research cost of chidamide was about $70 million, or about one-tenth what it would have cost to develop in the U.S.

“They are a good example of the potential for innovation in China,” said Angus Cole, director at Monitor Deloitte and pharmaceuticals and biotechnology lead in China.

China’s spending on pharmaceuticals is expected to top $107 billion in 2015, up from $26 billion in 2007, according to Deloitte China. It will become the world’s second-largest drug market, after the U.S., by 2020, according to an analysis published last year in the Journal of Pharmaceutical Policy and Practice.

via A New Cancer Drug, Made in China – China Real Time Report – WSJ.

08/07/2014

Indian Budget 2014: Biocon chief wants more R&D incentives, fewer essential drugs – Reuters

India’s $15 billion healthcare industry has taken hits on several fronts in recent years, from slow approvals for drugs in clinical trials to several run-ins with the U.S. Food and Drug Administration over the quality of its generic drugs.

Market growth fell to less than 10 percent last year after the increase in the number of drugs that the government said should be subject to price caps so that poor and middle-class people could afford them (Only 15 percent of India’s 1.2 billion people have health insurance).

Now, with Prime Minister Narendra Modi hinting at a “bitter pill” to rescue India’s economy, the pharma industry wouldn’t want to be at the receiving end of tough decisions; it would be difficult for a business that’s used to making medicine instead of taking it.

via India Insight.

25/05/2013

* Guangzhou rice scare shows open government remains elusive

SCMP: “Cover-up of cadmium scandal reveals authorities’ reluctance to comply with 2007 rule on non-classified information

aefcdd092c1c898f0bef513c3c208613.jpg

Guangzhou rice scare shows open government remains elusive

Many Guangzhou residents have been worried and angry for more than a week after being told that nearly half the rice they buy from local markets may contain excessive levels of cadmium, a carcinogenic heavy metal.

The city’s Food and Drug Administration said on May 16 that it had checked 18 batches of rice between January and March and had found cadmium levels in eight of them exceeded the national food safety standard.

But it declined to disclose any information about the tainted rice, such as where it was produced and by which brands. The food-safety watchdog said it was “inconvenient” to share the information with the public but did not explain why.

The cover-up sparked a national outcry. Even some state-owned media criticised the regulator, saying the refusal to disclose the information was a crime.

After coming under a great deal of pressure, the watchdog disclosed the names of the rice producers last Saturday, but still refused to detail the amount of tainted rice sold.

The Guangzhou case is merely the tip of the proverbial iceberg in showing how reluctant mainland officials are to allow open access to government data.

The Regulations on Open Government Information, introduced by Beijing in 2007, say all levels of local government should make their non-classified information public.

The regulations set clear standards for the format authorities should follow when publishing and organising the data on their websites, because of concerns that members of the public would otherwise be unable to find the information they were looking for.

But six years later, mainland officials remain reluctant to publicise such information.”

via Guangzhou rice scare shows open government remains elusive | South China Morning Post.

Law of Unintended Consequences

continuously updated blog about China & India

ChiaHou's Book Reviews

continuously updated blog about China & India

What's wrong with the world; and its economy

continuously updated blog about China & India